on July 1, 2002
Published online before print July 1, 2002, doi: 10.1161/01.HYP.0000026668.50222.1E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 20, 2002
From the Department of Clinical Pathophysiology (K.O., M.O., T.N., N.N., M.Y.) and First Department of Internal Medicine (K.N., F.S., H.I., S.I.), Nagoya University Graduate School of Medicine, Nagoya; Nagoya University School of Health Sciences (M.I.), Nagoya; and Gifu International Institute of Biotechnology (Y.Y.), Mitake, Japan. * To whom correspondence should be addressed. E-mail: myokota{at}med.nagoya-u.ac.jp.
Abstract—The possible role of calcineurin in the attenuation of cardiac hypertrophy and fibrosis by blockade of the angiotensin II type 1 (AT1) receptor was investigated in Dahl salt-sensitive (DS) rats. The effect of the calcineurin inhibitor FK506 was also studied. DS rats progressively developed severe hypertension when fed a diet containing 8% NaCl from 7 weeks of age. In addition, marked cardiac hypertrophy and fibrosis were apparent and the activity of calcineurin and its mRNA expression in the myocardium was increased in these animals at 12 weeks in comparison with age-matched Dahl salt-resistant rats. The abundance of angiotensin-converting enzyme (ACE) and transforming growth factor (TGF)-ß1 mRNAs was also increased in the hearts of DS rats at 12 weeks. Treatment of DS rats with a non-antihypertensive dose of the selective AT1 receptor blocker candesartan (1 mg/kg per day) or FK506 (0.1 mg/kg per day) from 7 to 12 weeks attenuated both calcineurin activity and its mRNA expression in the heart, as well as the development of cardiac hypertrophy and fibrosis, without affecting cardiac function. Treatment with candesartan, but not FK506, prevented the upregulation of ACE and TGF-ß1 gene expression. Both candesartan and FK506 prevented the load-induced induction of fetal-type cardiac genes. These results demonstrate that AT1 receptor blockade attenuates the development of cardiac hypertrophy and fibrosis as well as the activation of calcineurin, without an antihypertensive effect, in rats with salt-sensitive hypertension. Calcineurin may be downstream from TGF-ß1 in AT1 receptor-mediated angiotensin II signaling in vivo.
Revised on March 18, 2002
AT1 Receptor Blockade Reduces Cardiac Calcineurin Activity in Hypertensive Rats
Kohzo Nagata;
Key words: hypertension, sodium-dependent • myocardium • hypertrophy • fibrosis • angiotensin II
This article has been cited by other articles:
 |
|
 |
|
  C. D. Garciarena, O. A. Pinilla, M. B. Nolly, R. P. Laguens, E. M. Escudero, H. E. Cingolani, and I. L. Ennis Endurance Training in the Spontaneously Hypertensive Rat: Conversion of Pathological into Physiological Cardiac Hypertrophy Hypertension, April 1, 2009; 53(4): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miyachi, H. Yazawa, M. Furukawa, K. Tsuboi, M. Ohtake, T. Nishizawa, K. Hashimoto, T. Yokoi, T. Kojima, T. Murate, et al. Exercise Training Alters Left Ventricular Geometry and Attenuates Heart Failure in Dahl Salt-Sensitive Hypertensive Rats Hypertension, April 1, 2009; 53(4): 701 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tokudome, I. Kishimoto, T. Horio, Y. Arai, D. O. Schwenke, J. Hino, I. Okano, Y. Kawano, M. Kohno, M. Miyazato, et al. Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart Circulation, May 6, 2008; 117(18): 2329 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Tu, H. Sun, G. T. Bowden, and Q. M. Chen Involvement of oxidants and AP-1 in angiotensin II-activated NFAT3 transcription factor Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1248 - C1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. W. Cheng, K. Obata, M. Kuzuya, H. Izawa, K. Nakamura, E. Asai, T. Nagasaka, M. Saka, T. Kimata, A. Noda, et al. Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure Hypertension, November 1, 2006; 48(5): 979 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagata, K. Obata, J. Xu, S. Ichihara, A. Noda, H. Kimata, T. Kato, H. Izawa, T. Murohara, and M. Yokota Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats Hypertension, April 1, 2006; 47(4): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ichihara, A. Noda, K. Nagata, K. Obata, J. Xu, G. Ichihara, S. Oikawa, S. Kawanishi, Y. Yamada, and M. Yokota Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure Cardiovasc Res, February 15, 2006; 69(3): 726 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tokudome, T. Horio, I. Kishimoto, T. Soeki, K. Mori, Y. Kawano, M. Kohno, D. L. Garbers, K. Nakao, and K. Kangawa Calcineurin-Nuclear Factor of Activated T Cells Pathway-Dependent Cardiac Remodeling in Mice Deficient in Guanylyl Cyclase A, a Receptor for Atrial and Brain Natriuretic Peptides Circulation, June 14, 2005; 111(23): 3095 - 3104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ishizaka, K. Saito, E. Noiri, M. Sata, H. Ikeda, A. Ohno, J. Ando, I. Mori, M. Ohno, and R. Nagai Administration of ANG II induces iron deposition and upregulation of TGF-{beta}1 mRNA in the rat liver Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R1063 - R1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Saito, N. Ishizaka, T. Aizawa, M. Sata, N. Iso-o, E. Noiri, I. Mori, M. Ohno, and R. Nagai Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-{beta}1 in the heart Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1836 - H1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D Molkentin Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs Cardiovasc Res, August 15, 2004; 63(3): 467 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Larkin, B. C. Frank, R. M. Gaspard, I. Duka, H. Gavras, and J. Quackenbush Cardiac transcriptional response to acute and chronic angiotensin II treatments Physiol Genomics, July 8, 2004; 18(2): 152 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kobayashi, S.-i. Mita, K. Yoshida, T. Honda, T. Kobayashi, K. Hara, S. Nakano, Y. Tsubokou, and H. Matsuoka Celiprolol Activates eNOS Through the PI3K-Akt Pathway and Inhibits VCAM-1 Via NF-{kappa}B Induced by Oxidative Stress Hypertension, November 1, 2003; 42(5): 1004 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wolk Calcineurin, myocardial hypertrophy, and electrical remodeling Cardiovasc Res, February 1, 2003; 57(2): 289 - 293. [Full Text] [PDF]
|
|